Uvadex/Therakos Photopheresis (methoxsalen/ECP) / Mallinckrodt  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Uvadex/Therakos Photopheresis (methoxsalen/ECP) / Mallinckrodt
2019-000894-22: Phase II multicenter study of UV irradiation with UvadexTM outside of the body plus standard steroid treatment for high risk acute Graft-versus-Host Disease Multizentrische Phase-II-Studie zur UV-Bestrahlung mit UvadexTM außerhalb des Körpers plus Standardbehandlung mit Steroiden bei akuter Spender-gegen-Empfänger-Erkrankung mit hohem Risiko

Not yet recruiting
2
72
Europe
Solution for blood fraction modification, UVADEX
Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf, Therakos, Inc.
New onset high risk acute GvHD following allogeneic SCT Neu auftretende akute GvHD mit hohem Risiko nach allogener SCT, New onset high risk acute Graft-versus-Host-Disease following allogeneic (of nonself origin) Stem Cell Transplantation Neu auftretende akute Spender-gegen-Empfänger-Erkrankung mit hohem Risiko nach Transplantation von Stammzellen, die nicht vom Patienten selbst stammen, Diseases [C] - Immune System Diseases [C20]
 
 
COPAVEHDI, NCT06133192: Steroids Versus ECP and Steroids as First-line Treatment of Grade II Acute GVHD

Not yet recruiting
2
42
Europe
Uvadex, Steroids
Central Hospital, Nancy, France
Graft Vs Host Disease
09/25
01/26
NCT05157581: Extracorporeal Photopheresis in Sezary Syndrome

Recruiting
2
15
US
Extracorporeal photopheresis (ECP), ECP, photopheresis, Methoxsalen Injection, Uvadex
Oleg E. Akilov, MD, PhD, Mallinckrodt
Sezary Syndrome
12/25
12/26
NCT04986605: Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis

Not yet recruiting
2
15
Canada
Extracorporeal Photopheresis (ECP), ECP, 8-mop, UVADEX
Lawson Health Research Institute, Mallinckrodt
Diffuse Cutaneous Systemic Sclerosis
12/26
06/27
NCT05680558: Photopheresis in Early-stage Mycosis Fungoides

Recruiting
2
74
US
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, UVADEX® with THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
Columbia University, Mallinckrodt, Inc.
Cutaneous T Cell Lymphoma, Mycosis Fungoides
12/25
07/26
2021-002073-26: Extracorporeal photopheresis as treatment for immune related adverse events after immunotherapy Extrakorporale Photopherese zur Behandlung von immunvermittelten unerwünschten Ereignissen nach einer Immuntherapie

Not yet recruiting
1/2
14
Europe
UVADEX, Sterile concentrate, UVADEX
Medical Center - University of Freiburg, University of Freiburg, Faculty of Medicine, Therakos EMEA Ltd
Immune related adverse events induced by treatment with immune checkpoint inhibitors (monoclocanl antibodies against PD-1, PD-L1 or CTLA-4) Immunvermittelte unerwünschte Ereignisse, die durch eine Behandlung mit Immun-Checkpoint-Inhibitoren (monoklonale Antikörper gegen PD-1, PD-L1 oder CTLA-4) induziert wurden, Immune related adverse events induced by treatment with immunotherapy Immunvermittelte unerwünschte Ereignisse durch eine Behandlung mit einer Immuntherapie, Diseases [C] - Cancer [C04]
 
 

Download Options